MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 ...
Study will highlight novel iNKT cell-based combinations in checkpoint-refractory diseaseData expected to inform immune modulation, treatment sequencing strategy, and clinical durability of response
MT
mink therapeutics
via Postregister - Corroborated by 2 others
Updated 4d ago

Source Verification
Corroboration Score: 3This story was independently reported by 3 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...


